In a 2019 interview, Bristol-Myers Squibb biologics development leader Henrik Andersen said Seattle’s ability to grow and retain large biotech companies depended on keeping skilled workers, coordinating education and internship pathways, taking corporate incentives seriously, and reinvesting local success in new ventures. Those were his views at the time—not a current assessment or a measured ranking of what drives biotech growth.
Why Andersen was weighing Seattle’s biotech future
Andersen had worked at Seattle-based ZymoGenetics before Bristol-Myers Squibb acquired it, and he experienced the later closure of the company’s Seattle outpost. In May 2019, Bristol-Myers Squibb’s proposed acquisition of Celgene also raised questions about Juno Therapeutics, then a Celgene-owned Seattle biotech. GeekWire reported the announced cash-and-stock deal at $74 billion; that is the contemporaneous transaction figure, not a current valuation.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Biotechnology for Beginners | $28.52 | Buy on Amazon |
| 2 |
|
Biotechnology Demystified | $20.36 | Buy on Amazon |
| 3 |
|
Biotechnology for Beginners | $132.98 | Buy on Amazon |
| 4 |
|
Biotechnology | $103.82 | Buy on Amazon |
| 5 |
|
Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform our Lives, Work, and... | $14.80 | Buy on Amazon |
Drawing on that experience, Andersen framed the challenge as both attracting large companies and retaining the people and institutions that help make the region innovative. His comments were qualitative; the interview did not measure Seattle’s biotech workforce, investment flows, or the impact of particular incentives.
Build a talent pipeline—and make it easier to hire locally
Andersen argued that Seattle needed to develop and retain talent, not simply educate people who might leave for opportunities elsewhere. He called for regional leaders to collaborate on education and internship programs that connect local graduates with biotech employers. Internships, in this framing, are a practical bridge between training and industry work.
Do these 3 things before closing this tab:
1Scan for outdated or missing drivers - takes under a minute2Repair Windows errors before they cause bigger problems3Fix the driver behind crashes, sound loss and screen glitches#1 Best Overall
- New
- Mint Condition
- Dispatch same day for order received before 12 noon
- Guaranteed packaging
- No quibbles returns
“The talent is here,” he said. “And I think that Seattle needs to retain the talent to remain innovative.”
He also pointed to a related challenge: recruiting senior employees is difficult when a region lacks a critical mass of organizations. A larger network of employers and research institutions can make it easier for experienced people to find roles and for companies to build teams, but Andersen did not quantify the effect or specify a hiring target.
Rank #2
Recognize that incentives are part of corporate location decisions
Andersen said a company’s finance function may weigh incentives alongside innovation, people, and talent when considering where to locate or expand. His point was not that incentives alone determine a decision, but that strong scientific credentials do not make financial considerations disappear.
“In the end, there’s all the soft values: great innovation, great people, great talent. But guess what? There’s also a finance function of [Bristol-Myers] and other companies, and they do look at things like [incentives],” Andersen said.
Special offer. See more information about Outbyte and uninstall instructions. Please review EULA and Privacy policy.Rank #3
The bracketed wording is how the quotation appeared in GeekWire’s published interview. Andersen offered no incentive figures or comparison with other cities, so the interview supports taking incentives seriously—not a conclusion about which incentive package Seattle should adopt.
Use institutional density to support innovation
Andersen identified institutions that could contribute to a critical mass for life-sciences innovation: the University of Washington, Fred Hutch, Seattle Children’s, the Bill & Melinda Gates Foundation, and the Allen Institute. Their presence, in his view, was part of Seattle’s foundation for biotech. The interview did not assess the institutions’ individual economic contributions or compare Seattle’s research base with another region.
Rank #4
Recycle the gains from successful companies into new ventures
Andersen saw an opportunity to direct money generated by successful local companies toward smaller, new companies. That idea links established biotech success to the next generation of startups: locally generated capital could help finance new ventures rather than leaving the region’s innovation base dependent on attracting outside investment alone.
He did not provide a forecast, an estimate of available capital, or a specific investment mechanism. The proposal is therefore a strategic possibility, not a quantified funding plan.
Best Value
What the interview does—and does not—establish
Andersen’s four connected levers were talent development and retention, competitive attention to incentives, a dense network of research and healthcare institutions, and reinvestment in startups. They describe his 2019 perspective on how Seattle could grow and keep large biotech companies. The interview provides no comparable regional data, economic impact estimates, or ranking of those levers. For the historical account and full context, see James Thorne’s May 24, 2019 GeekWire interview.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
